The Latest
-
Stock via Getty Images
First 90 DaysAs its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing
Simone Steiner recently joined the French company to set the stage for launch.
-
Andrew Harnik via Getty Images
Trump says ‘very high’ pharmaceutical tariffs coming soon
While Trump indicated drug levies would be as high as 200%, he added that pharma firms would first be given time to bring manufacturing back to the U.S.
-
Getty Images via Getty Images
Is biopharma dealmaking getting hot again?
With pharma’s finger on the M&A button, three of the biggest deals of the year are breadcrumbs that could lead to a full-on resurgence.
-
Stock via Getty Images
The MEK effect on cancer — a slow and steady approach to drug resistance
Immuneering Corporation’s investigational MEK inhibitor aims to outpace cancer while reducing resistance and side effects.
-
stock via Getty Images
GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down
As more drugmakers aim for the lucrative weight loss market, patient challenges linger.
-
E+ via Getty Images
Can China sustain a surge in oncology drug innovation?
The country’s trajectory may get a boost from anticipated results of a Keytruda rival’s U.S. trials.
-
iStock via Getty Images
AI’s ‘massive transition’ in biopharma shapes leadership mindsets — tension and all
The AI revolution is driving tension between new technology and the traditional approaches in drugmaking. Biopharma leaders are trying to navigate those turbulent waters.
-
Stock via Getty Images
First 90 DaysA biopharma bolsters patient centricity and trial diversity goals through newly created role
Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.
-
Andrew Harnik via Getty Images
FDA’s new mission to speed drug reviews
FDA Commissioner Dr. Marty Makary is leading a handful of controversial new initiatives to make the drug review process more streamlined.
-
Justin Sullivan via Getty Images
3 of the year’s most notable FDA nods
The agency has granted approvals steadily in the first part of the year, including nods for several breakthrough therapies.
-
hxdbzxy via Getty Images
Top pharma and biotech conferences in the second half of 2025 and beyond
Mark your calendars for the most important industry conferences in the second half of 2025 and into next year.
Updated June 27, 2025 -
Grandbrothers via Getty Images
Biopharma is on edge about NIH funding cuts and what the future holds for research
Proposed cuts to public funding for early science have led to an outcry in scientific circles. For biopharma leaders, the effects are still up in the air.
-
Elijah Nouvelage via Getty Images
CDC panel, newly remade by RFK Jr., questions vaccine evidence
New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at other established shots, like those for measles and hepatitis B.
-
Stock via Getty Images
After myriad failures, a new wave of ALS drugs approaches
Several drugmakers anticipate trial results and FDA submissions in 2025 and 2026, including some still overcoming past failures.
-
Permission granted by Parabilis
Q&AHow a Big Pharma veteran looks to stand out in biotech as a unique ‘drug hunter’
J&J’s former head of R&D, now CEO of Parabilis Medicines, aims to remain above the biotech fray by taking on unique targets from which others have steered clear.
-
Stock via Getty Images
Biogen scores Cannes Festival win with dark humored campaign
The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.
-
Stock via Getty Images
Megablockbusters are the holy grail. Here’s how drugmakers are getting there.
More drugs surpassed $10 billion in revenue last year than ever before.
-
iStock via Getty Images
Biotech’s turning point: for every challenge, an opportunity in disguise
As hurdles litter biotech’s future, forward-thinking leaders look for ways to leap to the other side.
-
stock via Getty Images
Is DTC pharma advertising coming to an end?
A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.
-
Kayla Bartkowski via Getty Images
FDA to speed reviews for drugs supporting ‘national interests’
A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.
-
Stock via Getty Images
How a patient group tackled research diversity for one disease and triggered change for pharma
A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.
-
Kevin Dietsch via Getty Images
Locked in a federal stalemate, states take PBM reform into their own hands
Arkansas is leading the nation in banning PBMs from owning pharmacies, as other states advance new restrictions.
-
Stock via Getty Images
Will pharma finally score a policy win for 340B?
The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.
-
Permission granted by Michael Moenning, Northlight Studio
ProfileA day in the life of GSK’s U.S. president
How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.
-
Getty Images via Getty Images
Can ‘reputational pull’ save biotech from pharma’s image problem?
A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.
